ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias

Eczema trials near Cincinnati, OH, USA:

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis Eczema
Drug: Placebo
Drug: ANB032

Phase 2

AnaptysBio
AnaptysBio

Mason, Ohio, United States and 83 other locations

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Active, not recruiting
Atopic Dermatitis (AD)
Drug: Ruxolitinib Cream

Phase 3

Incyte
Incyte

Dayton, Ohio, United States and 37 other locations

Global Assessment for Atopic Dermatitis (vIGA-AD).* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Cincinnati, Ohio, United States and 196 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Dayton, Ohio, United States and 320 other locations

The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib (ABT-494)

Phase 1

AbbVie
AbbVie

Cincinnati, Ohio, United States and 17 other locations

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

Enrolling
Atopic Dermatitis
Drug: ruxolitinib cream

Phase 4

Incyte
Incyte

Dayton, Ohio, United States and 30 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Cincinnati, Ohio, United States and 429 other locations

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: APG777

Phase 2

Apogee Therapeutics, Inc.

Mason, Ohio, United States and 16 other locations

The purpose of this trial is to test different doses of the trial medicine (LEO 138559) at treating moderate to severe atopic dermatitis in adults. T...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LEO 138559

Phase 2

LEO Pharma
LEO Pharma

Cincinnati, Ohio, United States and 72 other locations

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 3

Galderma
Galderma

Cincinnati, Ohio, United States and 342 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems